Loading viewer...
investor_presentation
Format: PDF investor_presentation
NeuroSense Therapeutics is developing novel therapies for neurodegenerative diseases including ALS (amyotrophic lateral sclerosis). The company presented significant top-line results from its Phase 2b clinical trial, with biomarker results expected in H1 2024 and an expedited regulatory pathway under orphan drug designation.
investor_presentation
19 Pages
Spin Master Corp
Karyopharm Therapeutics Investor Presentation — February 2022
investor_presentationinvestor_presentation
34 Pages
Karyopharm Therapeutics Inc.